News

DAPT study

Patients who took dual antiplatelet therapy medications beyond the standard 12 months after coronary stent placement were significantly less likely to develop blood clots within their stents or to...

The actions — or inaction — of patients should be considered in programs designed to improve care and patient outcomes, according to a report released by the American College of Cardiology,...

Heart disease and stroke are the leading causes of death and disability among people with Type 2 diabetes. At least 65 percent of people with diabetes die from some form of heart disease or stroke...

October 15, 2014 — Novartis Pharmaceuticals Canada Inc. revealed, in the largest heart failure study to date, that its investigational heart failure medicine, LCZ696, was superior to the ACE-...

Researchers have discovered a previously unknown cardiac molecule that could provide a key to treating and preventing heart failure...

Twelve-month Data St. Jude Medical EnligHTN Renal Denervation System

St. Jude Medical Inc. announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN Renal...

New analyses and extended follow-up from the BRIGHT study demonstrated that bivalirudin remained superior to both heparin monotherapy and heparin plus tirofiban for patients with acute myocardial...

According to a new study, patients receiving six months of dual antiplatelet therapy (DAPT) after receiving a second-generation drug-eluting stent (DES) appeared to have similar outcomes to...

Study Blood Thinner Heart Attack Patients

The largest prospective longitudinal study of acute myocardial infarction (MI) patients offers unique insight into the use, safety and effectiveness of blood thinners prasugrel and clopidogrel in...

September 19, 2014 — A new study investigating different durations of triple therapy for anticoagulation after drug-eluting stent (DES) implantation demonstrated that six weeks of drug therapy was...

Professors Updated Information Aspirin Heart Attack Prevention

The first researcher in the world to discover that aspirin prevents a first attack, Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the...

heart attack, JAMA, American Medical Association, acute coronary syndrome

In patients who experienced an acute coronary syndrome (ACS) event, use of the drug darapladib to inhibit the enzyme lipoprotein-associated phospholipase A2 did not reduce the risk of recurrent...

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced results from the X-VeRT trial, demonstrating once-daily rivaroxaban may be an alternative...

August 28, 2014 — Renal artery stenting to open blockages in the kidney arteries may benefit patients who have historically been excluded from modern clinical trials, according to new...

The American College of Cardiology and the American Heart Association today released a revised guideline for minimizing the risk of cardiovascular complications around the time of...

The mantra for treatment for high blood pressure has been "the lower, the better," but that goal can potentially put patients at risk of kidney failure or death, according to a Kaiser Permanente...

New data revealing the reduction in cardiovascular (CV) deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction (HF-REF) will be presented at the world's largest...

U.S. Department of Justice Close Investigation PLATO Clinical Trial Ticagrelor

AstraZeneca announced it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial that tested the safety and...

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43...

Clinical Study Heart Vaccine Pharmaceutical

Researchers at Wayne State University have made a fundamental discovery and, in subsequent collaboration with scientists at La Jolla Institute for Allergy and Immunology (LIAI), are one step...